SAGE 718

Drug Profile

SAGE 718

Alternative Names: SAGE-718

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SAGE Therapeutics
  • Class Small molecules
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Smith-Lemli-Opitz syndrome
  • Preclinical Encephalitis

Most Recent Events

  • 07 Aug 2018 SAGE Therapeutics initiates a multiple ascending dose phase I trial in healthy volunteers before August 2018
  • 07 Aug 2018 SAGE Therapeutics plans clinical development in Central nervous system disorders subject to positive results from a multiple ascending dose phase I trial
  • 03 May 2018 Sage Therapeutics plans a phase I multiple ascending dose trial in volunteers in second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top